Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 31,823 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 31,823 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.41, for a total transaction of $681,330.43. Following the completion of the transaction, the president owned 922,240 shares in the company, valued at $19,745,158.40. This trade represents a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Arcus Biosciences Trading Up 6.9%

Shares of Arcus Biosciences stock traded up $1.50 on Wednesday, reaching $23.19. 1,239,263 shares of the company’s stock were exchanged, compared to its average volume of 1,473,878. The company has a market capitalization of $2.50 billion, a P/E ratio of -6.74 and a beta of 0.77. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $26.40. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The firm’s 50-day moving average is $22.49 and its two-hundred day moving average is $15.36.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. During the same period in the prior year, the firm earned ($1.00) earnings per share. Arcus Biosciences’s revenue was down 45.8% on a year-over-year basis. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in shares of Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after buying an additional 1,021 shares during the last quarter. SBI Securities Co. Ltd. raised its position in Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. Abich Financial Wealth Management LLC purchased a new position in Arcus Biosciences in the third quarter valued at about $69,000. CWM LLC boosted its stake in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in shares of Arcus Biosciences by 34.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after acquiring an additional 1,796 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RCUS shares. Bank of America boosted their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Wells Fargo & Company boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a research note on Monday, December 15th. The Goldman Sachs Group lifted their price objective on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Finally, Truist Financial set a $30.00 target price on shares of Arcus Biosciences in a research report on Friday, December 12th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.